Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1CNS 1

Conditions

Melanoma 8Neoplasms 2Recurrence 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced Melanoma 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1

Interventions

Blood Specimen Collection 38pembrolizumab 36Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 18Exercise 17Carboplatin 16Nivolumab 15atezolizumab 14Cisplatin 14Drug Therapy 13Paclitaxel 12Fluorouracil 12Cyclophosphamide 12Cetuximab 12Trastuzumab 10Leucovorin 10Docetaxel 10Dexamethasone 10Pemetrexed 9Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Opdualag × Clear all
NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Australian & New Zealand Children's Haematology/Oncology Group

Phase 1/2 Recruiting
90 enrolled
CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT05970497 2025-05-18

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Krystal Biotech, Inc.

Phase 1/2 Recruiting
240 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡